Table 1.

Patient demographics. Patients were allocated to 4 treatment groups as described in the study protocol.

		NAC alone	NAC + 2 μmol/kg calmangafodipir	NAC + 5 μmol/kg calmangafodipir	NAC + 10 μmol/kg calmangafodipir
		(N = 6)	(N = 6)	(N = 6)	(N = 6)
Age (years) at randomisation	Mean (SD)	32.2 (12.5)	42.5 (13.1)	42.7 (12.7)	22.7 (3.3)
	Median	30.0	41.0	42.5	22.0
	Minimum, Maximum	19, 52	27, 66	26, 59	19, 28
Sex	Male	4 (67%)	2 (33%)	2 (33%)	3 (50%)
	Female	2 (33%)	4 (67%)	4 (67%)	3 (50%)
Time from ingestion of paracetamol to hospital presentation (hours)	Mean (SD)	8.8 (6.2)	6.0 (6.2)	5.8 (7.2)	4.9 (5.2)
	Median	7.6	2.6	2.1	2.1
	Minimum, Maximum	1.9, 16.6	1.4, 15.1	1.3, 19.5	1.4, 14.6
Type of overdose	Acute, ≤8 h to NAC	2 (33%)	4 (67%)	4 (67%)	4 (67%)
	Acute, >8 h to NAC	3 (50%)	2 (33%)	2 (33%)	1 (17%)
	Staggered intentional	0 (0%)	0 (0%)	0 (0%)	1 (17%)
	Supra-therapeutic	1 (17%)	0 (0%)	0 (0%)	0 (0%)
Presentation paracetamol concentration (mg/L)	Mean (SD)	76 (81)	127 (90)	74 (44)	127 (47)
	Median	58	114	88	132
	Minimum, Maximum	8, 228	16, 272	8, 117	76, 201
Total paracetamol ingested (mg/kg)	Mean (SD)	185 (156)	235 (77)	229 (72)	397 (476)
	Median	116	222	244	227
	Minimum, Maximum	28, 418	154, 340	142, 303	88, 1357
Time from ingestion of paracetamol to start of NAC treatment (hours)	Mean (SD)	12.1 (5.2)	9.8 (5.7)	10.2 (6.9)	8.6 (4.1)
	Median	10.3	6.5	7.3	6.7
	Minimum, Maximum	7.7, 20.3	5.5, 17.9	6.0, 23.8	5.3, 16.0
Time from ingestion of paracetamol to start of calmangafodipir (hours)	Mean (SD)	N/A	12.6 (6.8)	10.8 (4.1)	11.8 (5.4)
	Median	N/A	9.5	9.0	8.9
	Minimum, Maximum	N/A	8.5, 26.1	7.6, 18.0	7.6, 26.1
Any other drugs ingested	Yes	5 (83%)	4 (67%)	5 (83%)	5 (83%)
	No	1 (17%)	2 (33%)	1 (17%)	1 (17%)
Serum creatinine (μmol/L)	Mean (SD)	74.7 (11.0)	67.5 (13.3)	67.3 (17.2)	69.5 (13.1)
	Median	73.5	63.5	66.0	68.5
	Minimum, Maximum	59, 92	57, 94	50, 98	53, 86